發(fā)布時(shí)間：2018-03-24 03:14

  本文選題：卵巢腫瘤　切入點(diǎn)：微小核糖核酸　出處：《河北醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:卵巢上皮性腫瘤(Epithelial ovarian tumor)是女性常見生殖器腫瘤之一,是影響女性生命及生活質(zhì)量的疾病之一,包括良性、交界性和惡性。而卵巢上皮性惡性腫瘤(Epithelial ovarian cancer,EOC)是常見婦科惡性腫瘤之一,其病死率居女性腫瘤中的第5位。微小核糖核酸(Micro RNA,miRNA)是一類長(zhǎng)約19~24nt的非編碼小RNA,在轉(zhuǎn)錄后水平調(diào)節(jié)基因的表達(dá)。在很多生物學(xué)過(guò)程,包括腫瘤發(fā)生發(fā)展、侵襲與轉(zhuǎn)移、耐藥和復(fù)發(fā)等過(guò)程中均可發(fā)現(xiàn)miRNA的表達(dá)。本實(shí)驗(yàn)檢測(cè)初治卵巢上皮性癌原發(fā)灶、初治卵巢上皮性癌轉(zhuǎn)移灶、復(fù)發(fā)卵巢上皮性癌和卵巢上皮性良性腫瘤組織中,miRNA-3198、miRNA-8084、miRNA-7515和miRNA-3613-3P四種miRNA的表達(dá)情況,比較各組表達(dá)差異,并探討其可能的機(jī)制,以期發(fā)現(xiàn)miRNA在卵巢上皮性癌的發(fā)生、侵襲與轉(zhuǎn)移及復(fù)發(fā)中的作用,為卵巢上皮性癌的診治提供新的方向。方法:1無(wú)菌條件下收集在白求恩國(guó)際和平醫(yī)院從2010年10月至2016年11月手術(shù)的臨床組織標(biāo)本,共60例,包括初治卵巢上皮性癌原發(fā)灶組織(A組)15例、初治卵巢上皮性癌轉(zhuǎn)移灶組織(B組)15例、復(fù)發(fā)卵巢上皮性癌組織(C組)16例和卵巢上皮性良性腫瘤組織(D組)14例。所有組織標(biāo)本置于-80℃冰箱冷藏。初治卵巢上皮性癌所有患者手術(shù)前均未行任何相關(guān)手術(shù)及輔助治療。復(fù)發(fā)卵巢上皮性癌所有患者滿足二次減滅術(shù)的適應(yīng)癥:距離最后一次化療結(jié)束后復(fù)發(fā)間隔時(shí)間6~12個(gè)月;腫瘤病灶孤立且可完整切除;無(wú)腹水。所有標(biāo)本均有術(shù)后病理確診。2實(shí)時(shí)熒光定量聚合酶鏈?zhǔn)椒磻?yīng)(Quantitative Real-time polymerase chain reaction,q RT-PCR)檢測(cè)并用統(tǒng)計(jì)學(xué)方法分析結(jié)果。結(jié)果:1 miRNA-3198在A、B、C和D四組中表達(dá)情況的比較:A、B、C和D四組miRNA-3198的表達(dá)水平不全相同,具有統(tǒng)計(jì)學(xué)差異(χ2=20.32,P0.001)。進(jìn)一步進(jìn)行兩兩比較,結(jié)果是:B組miRNA-3198的表達(dá)水平與其余三組均不相同,均具有統(tǒng)計(jì)學(xué)差異(P0.05),B組是四組中miRNA-3198表達(dá)水平最低的一組。另外,A組低于D組,具有統(tǒng)計(jì)學(xué)差異(P0.05);C組低于D組,具有統(tǒng)計(jì)學(xué)差異(P0.05)。D組是四組中miRNA-3198表達(dá)水平最高的一組。而A組與C組的表達(dá)水平無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。2 miRNA-7515在A、B、C和D四組中表達(dá)情況的比較:A、B、C和D四組miRNA-7515的表達(dá)水平不全相同,具有統(tǒng)計(jì)學(xué)差異(χ2=19.23,P0.001)。進(jìn)一步進(jìn)行兩兩比較,結(jié)果是:A、B、C三組miRNA-7515的表達(dá)水平與D組均不相同,均具有統(tǒng)計(jì)學(xué)差異(P0.05),D組是四組中miRNA-7515表達(dá)水平最高的一組,而A、B、C三組miRNA-7515的表達(dá)水平無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。3 miRNA-8084在A、B、C和D四組中表達(dá)情況的比較:A、B、C和D四組miRNA-8084的表達(dá)水平不全相同,具有統(tǒng)計(jì)學(xué)差異(χ2=18.70,P0.001)。進(jìn)一步進(jìn)行兩兩比較,結(jié)果是:A、B、C三組miRNA-8084的表達(dá)水平與D組均不相同,均具有統(tǒng)計(jì)學(xué)差異(P0.05),D組是四組中miRNA-8084表達(dá)水平最高的一組,而A、B、C三組miRNA-8084的表達(dá)水平無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。4 miRNA-3613-3P在A、B、C和D四組中表達(dá)情況的比較:A、B、C和D四組miRNA-3613-3P的表達(dá)水平不全相同,具有統(tǒng)計(jì)學(xué)差異(χ2=17.81,P0.001)。進(jìn)一步進(jìn)行兩兩比較,結(jié)果是:B組和C組中miRNA-3613-3P的表達(dá)水平均低于A組,具有統(tǒng)計(jì)學(xué)差異(P0.05)。B組和C組miRNA-3613-3P的表達(dá)水平均低于D組,具有統(tǒng)計(jì)學(xué)差異(P0.05)。而A組和D組miRNA-3613-3P的表達(dá)水平無(wú)統(tǒng)計(jì)學(xué)差異(P0.05),B組和C組miRNA-3613-3P的表達(dá)水平無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論:1 miRNA-3198在初治卵巢上皮性癌原發(fā)灶、初治卵巢上皮性癌轉(zhuǎn)移灶和復(fù)發(fā)卵巢上皮性癌組織中均為低表達(dá),在初治卵巢上皮性癌轉(zhuǎn)移灶組織中的表達(dá)水平最低,可能參與卵巢癌的發(fā)生發(fā)展、轉(zhuǎn)移及復(fù)發(fā)。2 miRNA-7515在初治卵巢上皮性癌原發(fā)灶、初治卵巢上皮性癌轉(zhuǎn)移灶和復(fù)發(fā)卵巢上皮性癌組織中均為低表達(dá),可能參與卵巢癌的發(fā)生。3 miRNA-8084在初治卵巢上皮性癌原發(fā)灶、初治卵巢上皮性癌轉(zhuǎn)移灶和復(fù)發(fā)卵巢上皮性癌組織中均為低表達(dá),可能參與卵巢癌的發(fā)生。4 miRNA-3613-3P在初治卵巢上皮性癌轉(zhuǎn)移灶和復(fù)發(fā)卵巢上皮性癌組織中均為低表達(dá),可能參與卵巢癌的轉(zhuǎn)移與復(fù)發(fā)。
[Abstract]:Objective: ovarian epithelial tumor (Epithelial ovarian tumor) is one of the common female genital tumors, is one of the female, and the quality of life of diseases including benign, borderline and malignant and malignant ovarian epithelial tumor (Epithelial ovarian, cancer, EOC) is one of the most common gynecologic malignant tumor, the mortality rate among women in tumor fifth. MicroRNAs (Micro RNA miRNA) is a class of about 19~24nt non small RNA encoding, regulate gene expression at the post transcriptional level. In many biological processes, including tumorigenesis, invasion and metastasis, the expression of miRNA can be found in the process of drug resistance and relapse. The early detection treatment of ovarian carcinoma, metastasis of early treatment of ovarian cancer, recurrent epithelial ovarian cancer and benign ovarian epithelial tumor tissues, miRNA-3198, miRNA-8084, miRNA-7515 and miRNA-3613-3P four M The expression of iRNA, compare the expression differences, and to explore its possible mechanism, in order to find the miRNA in epithelial ovarian cancer, invasion and metastasis and recurrence of the role, to provide a new direction for the diagnosis and treatment of ovarian cancer. Methods: in Heping Hospital from October 2010 to November 2016 Bethune International clinical surgery 1 specimens were collected under sterile conditions, a total of 60 cases, including primary tumor tissue of untreated epithelial ovarian cancer (A group) 15 cases, metastatic tissue of untreated epithelial ovarian cancer (B group) 15 cases, the recurrence of epithelial ovarian cancer (C group) and 16 cases of benign ovarian epithelial tumors (D group) 14 cases. All tissue specimens were placed in the refrigerator. C -80 initial treatment of ovarian cancer in all patients before surgery had no surgery and adjuvant treatment of recurrent epithelial ovarian cancer. All patients meet the two cytoreductive surgery indications: the last After the end of chemotherapy and recurrence interval of 6~12 months; tumor lesions were isolated and complete resection; no ascites. All specimens had postoperative real-time fluorescence quantitative polymerase chain reaction (Quantitative Real-time.2 and pathological diagnosis of polymerase chain reaction, Q RT-PCR) detection and statistical analysis results. Results: 1 miRNA-3198 in A, B, expression the comparison between the four groups in C and D: A, B, C and D expression level of miRNA-3198 in the four groups are not all the same, with statistical difference (2=20.32, P0.001). A further 22 comparison, the result is: the expression level of B in group miRNA-3198 and the other three groups are not the same, the differences were all statistically significant (P0.05), B group is the lowest level of the expression of miRNA-3198 in the four groups of a group. In addition, the A group was lower than that of D group, with statistical difference (P0.05); C group than in D group, with statistical difference (P0.05) of.D group is the four group the expression of miRNA-3198 in the highest level of a 緇，

本文編號(hào)：1656458